Enterofuril (nifuroxazide) capsules 200 mg. №16


Manufacturer: Bosnia and Herzegovina

Acute diarrhea of infectious etiology.



Enterofuril №16 Composition

active substance: 1 hard capsule contains 100 mg or 200 mg nifuroxazide
excipients: corn starch, sucrose, powdered cellulose, magnesium stearate. Gelatin capsule Enterofuril 100 mg contains titanium dioxide (E 171), quinoline yellow (E 104), azorubin (E 122) and ponso 4R (E124), gelatin gelatin capsule Enterofuril 200 mg contains titanium dioxide (E 171), iron oxide yellow ( E172), gelatin.

Enterofuril №16 Dosage form

The capsules are hard.

Basic physical and chemical properties:

oblong hard gelatin capsules, consisting of a body and a lid, yellow (Enterofuril 100 mg) or ocher-yellow (Enterofuril 200 mg), filled with granulate or slightly compressed yellow granulate, which disintegrates under light pressure. Capsule size 2 (Enterofuril 100 mg) or 0 (Enterofuril 200 mg).

Pharmacological group

Antimicrobial agents used to treat intestinal infections. ATX code A07A X03.

Pharmacological properties

Enterofuril №16 Pharmacodynamics.

Nifuroxazide is an antimicrobial drug derived from nitrofuran. The mechanism of action is not fully understood. The antimicrobial and antiparasitic properties of nifuroxazide are possibly due to the presence of an amino group. Local activity and the lack of penetration into the organs and tissues of the body makes nifuroxazide unique in comparison with other nitrofuran derivatives, since there is no systemic effect of this antidiarrheal drug. Effective against gram-positive and gram-negative bacteria: Streptococcus pyogenes, Staphylococcus aureus, E. coly, Salmonellae, Shigellae.


After oral administration, nifuroxazide is practically not absorbed from the gastrointestinal tract and does not enter the organs and tissues, 99% of the applied drug remains in the intestine. Nifuroxazide metabolism occurs in the intestine, about 20% of the amount taken is excreted unchanged. Nifuroxazide and its metabolites are excreted in the feces. The rate of elimination of the drug depends on the amount of the drug taken and on the motility of the gastrointestinal tract. In general, the withdrawal of nifuroxazide is slow; it remains in the gastrointestinal tract for a long time.

In therapeutic doses, nifuroxazide practically does not suppress the normal intestinal microflora, does not cause the appearance of resistant microbial forms, as well as the development of cross-resistance of bacteria to other antibacterial drugs. The therapeutic effect is achieved from the first hours of treatment.


Acute diarrhea of ​​infectious etiology.


Hypersensitivity to nifuroxazide, other 5-nitrofuran derivatives or other components of the drug.

Interaction with other medicinal products and other forms of interaction

Nifuroxazide is not recommended to be used simultaneously with sorbents, drugs that contain alcohol, drugs that can cause antabuse reactions, and drugs that depress the central nervous system.

Application features

Treatment with Nifuroxazide does not exclude dietary regimen and rehydration. If diarrhea persists after 3 days of treatment, the dosage should be reviewed and a decision should be made to rehydrate. If necessary, apply concomitant rehydration therapy, depending on the age and condition of the patient and the intensity of the diarrhea.

In the case of prescribing oral or intravenous rehydration, it is necessary to follow the instructions for the dilution and use of the solutions intended for this. If there is no need for such rehydration, it is necessary to compensate for the loss of fluid by drinking a large number of drinks containing salt and sugar (based on the average daily requirement of 2 liters of water).

Consideration should be given to dietary recommendations during diarrhea: avoid eating fresh vegetables and fruits, spicy foods, frozen foods and drinks. Rice should be preferred. The decision to use dairy products is made on a case-by-case basis.

If diarrhea is accompanied by clinical manifestations indicating aggressive phenomena (deterioration of the general condition, fever, symptoms of intoxication), Enterofuril should be prescribed together with antibacterial drugs, used to treat intestinal infections, since the drug is not absorbed in the intestine and does not enter the systemic circulation. The drug should not be prescribed as monotherapy for the treatment of intestinal infections complicated by septicemia.

Enterofuril contains sucrose, which should be taken into account when prescribing the drug to patients with diabetes mellitus. It is not recommended to appoint patients with hereditary disorders of tolerance to sucrose, fructose.

During treatment, alcohol consumption is strictly prohibited due to the risk of developing a disulfiram-like reaction, which is manifested by exacerbation of diarrhea, vomiting, abdominal pain, a feeling of heat on the face and upper body, hyperemia, tinnitus, difficulty breathing, tachycardia.